J. Goldman & Co’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-166,550
Closed -$5.34M 520
2022
Q1
$5.34M Buy
+166,550
New +$4.78M 0.24% 117

Other funds holding SRRA

J. Goldman & Co's SRRA Position: Q2 2022 in Review

J. Goldman & Co sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2022, closing a stake of 166,550 shares — an estimated $5.34M sold.

J. Goldman & Co first reported a position in SRRA in Q1 2022 and held it in 1 quarter. The position peaked at $5.34M in Q1 2022. 109 funds tracked by Wall St. Rank hold SRRA as of Q2 2022.

  • J. Goldman & Co reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • J. Goldman & Co sold 166,550 Sierra Oncology, Inc. Common Stock shares in Q2 2022, an estimated $5.34M.
  • J. Goldman & Co first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • J. Goldman & Co's Sierra Oncology, Inc. Common Stock position peaked at $5.34M in Q1 2022.
  • 109 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2022.

Based on J. Goldman & Co's 13F filing for Q2 2022, filed 15 Aug 2022.